This drives abnormal aggregation of TCA cycle-related proteins and cuproptosis, underscoring the central role of cuproptosis in IDD progression and proposing the SP1/FDX1 pathway as a novel therapeutic target. The gene discussed is FDX1; the disease is intervertebral disk degenerative disorder.